Heart Disease News and Research

Latest Heart Disease News and Research

Study finds canola-type rapeseed oil decreases fibrinogen level

According to research on fatty acids conducted at the universities of Helsinki and Tampere, the consumption of canola-type rapeseed oil decreases the level of fibrinogen detrimental to health in the body. The increased fibrinogen level, caused by an imbalance in essential fats in one's diet, decreases when saturated fatty acids are replaced with rapeseed oil.

9 Nov 2010

Omthera initiates ECLIPSE study for treatment of high triglycerides

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced the initiation of a randomized, open-label, four-way cross-over pharmacokinetics study to evaluate the bioavailability of Epanova, Omthera's lead compound for the treatment of very high triglycerides, in comparison to Lovaza, the leading prescription Omega-3.

9 Nov 2010

Teens abuse prescription drugs more than illegal drugs

According to the 2006 National Survey on Drug Use and Health, teens abuse prescription medications more than all illegal drugs combined, excluding marijuana. Many teens are under the misconception that these highly addictive, easily accessible drugs are "safer" than illicit drugs.

9 Nov 2010

China Sky third quarter total revenue decreases 16.3% to $36.2 million

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced financial results for the third quarter of 2010.

8 Nov 2010

$Beta blockers for high blood pressure also reduce fracture risk: Study$

Beta blockers for high blood pressure also reduce fracture risk: Study

Beta blockers, one of the most commonly used types of cardiovascular drugs, taken by about 20 per cent of the population, have been found to cut a person's incidence of bone fracture by half. This new and welcome side effect was reported by Professor Tuan Nguyen from Sydney's Garvan Institute of Medical Research and his Australian-based colleagues. “Indeed, we found that men and women who used beta-blockers had a 50 per cent lower risk of fracture than those not using beta blockers… We were very excited about the finding because, as you know, a lot of elderly people use beta blockers ... it’s a very significant public health issue,” he said.

8 Nov 2010

Thirteen myths about arthritis and rheumatic disease

A diagnosis of arthritis or another rheumatic disease can cause someone to feel anxious and even a little overwhelmed. Being a knowledgeable and empowered patient can help alleviate some of those feelings, and being able to navigate through the many misconceptions about arthritis and rheumatic diseases is vitally important.

8 Nov 2010

Positive results from Ardea's RDEA594 combination study with febuxostat or allopurinol for gout

Ardea Biosciences, Inc. announced positive results from two clinical studies of RDEA594 in combination with currently marketed drugs for the treatment of gout patients, febuxostat (Uloric®) and allopurinol.

8 Nov 2010

Crescendo Bioscience launches multi-biomarker blood test for RA

Crescendo Bioscience announced today the commercial launch of Vectra DA, its first-in-class multi-biomarker blood test designed to aid physicians in managing patients with rheumatoid arthritis (RA). Vectra DA analyzes 12 key serum biomarkers to produce a single objective score that quantifies RA disease activity.

8 Nov 2010

MAP Pharmaceuticals reports positive results from LEVADEX QT trial for migraine

MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.

8 Nov 2010

MedCath to sell Texsan Heart Hospital

MedCath Corporation announced today it has entered into a definitive agreement to sell substantially all the assets of Texsan Heart Hospital, owned by MedCath and its physician investors, to Methodist Healthcare System of San Antonio. The transaction is expected to close during MedCath's second fiscal quarter of 2011, which ends March 31, subject to regulatory approval and customary closing conditions.

8 Nov 2010

Apples lower risk for developing heart disease

Recent research out of the University of Michigan Health System – a premier academic medical center – has found that adding more apples and apple products to your diet may be an easy way to lower your risk for developing heart disease. More than one in three U.S. adults has one or more types of cardiovascular disease (CVD) according to the American Heart Association. Heart disease is the leading cause of death in the United States.

8 Nov 2010

Limiting inflammation can control accumulation of carotid atherosclerosis in RA patients

New data presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta show that systemic inflammation and rheumatoid arthritis disease activity may contribute to the progression of atherosclerosis in people with RA. The data also show that this progression may be modified favorably by TNF inhibitors and detrimentally by glucocorticoids.

8 Nov 2010

Angioblast Systems receives $1.2 million in grants under QTDP program

Regenerative medicine company, Mesoblast Limited, today announced that its United States associate company, Angioblast Systems, has been awarded $1.2 million in grants under the United States Government's Qualifying Therapeutic Discovery Project (QTDP) program.

8 Nov 2010

CARMAT signs agreement with Edwards Lifesciences for total artificial heart

CARMAT, the designer and developer of the world's most advanced artificial heart, today announced that it has signed an agreement with Edwards Lifesciences, the global leader in the science of heart valves and hemodynamic monitoring. According to this agreement, CARMAT will be using the Carpentier-Edwards' biological heart valves in its artificial heart.

8 Nov 2010

Helical CT scanning reduces lung cancer deaths

In a major new study announced today by the National Cancer Institute, researchers including Brown University biostatistian Constantine Gatsonis and his colleagues found that screening for lung cancer using helical CT scanning reduced lung cancer deaths by 20 percent compared to using chest X-rays.

8 Nov 2010

FDA announces reclassification for Full Field Digital Mammography Systems

The U.S. Food and Drug Administration today announced that it is easing the pathway to market for mammography systems that produce computerized X-ray images of the entire breast.

8 Nov 2010

Screening heavy smokers for lung cancer reduces chance of death, federal study finds

The Boston Globe: "Screening heavy smokers with sophisticated medical scanners modestly reduced their chance of dying from lung cancer, according to a federal study released yesterday that provides the first convincing evidence that testing could reduce the toll from the leading cause of cancer deaths. The preliminary findings from the National Cancer Institute were based on a gold-standard study that randomly assigned 53,000 current or former smokers without symptoms to be screened with a CT scanner or standard chest X-ray.

8 Nov 2010

Apricus receives $733,437 grants under QTDP program

Apricus Biosciences, Inc., today announced the award of three grants totaling $733,437 under the Qualifying Therapeutic Discovery Project program for PrevOnco, RayVa and Femprox which are the Company's development programs in cancer, autoimmune/cardiovascular and female sexual dysfunction, respectively.

8 Nov 2010

New findings could help scientists devise optimal therapies for Friedreich's ataxia

Scripps Research Institute scientists have taken a step closer to understanding the cause of Friedreich's ataxia, a debilitating neurological condition that affects tens of thousands of people worldwide, and so far has no cure.

8 Nov 2010

Hydroxychloroquine may reduce cardiac neonatal lupus in subsequent pregnancies: Research

Women with anti-SSA/Ro antibodies and a previous child who has heart block a condition where the electrical signal that makes the heart beat is damaged may potentially decrease their risk of delivering another child with life threatening heart disease by taking hydroxychloroquine (Plaquenil), according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010